1
|
Staljanssens D, De Vos WH, Willems P, Van Camp J, Smagghe G. Time-resolved quantitative analysis of CCK1 receptor-induced intracellular calcium increase. Peptides 2012; 34:219-25. [PMID: 21352882 DOI: 10.1016/j.peptides.2011.02.014] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2011] [Revised: 02/11/2011] [Accepted: 02/15/2011] [Indexed: 01/18/2023]
Abstract
Cholecystokinin (CCK) is a gastrointestinal hormone, which regulates many physiological functions such as satiety by binding to the CCK receptor (CCKR). Molecules, which recognize this receptor can mimic or block CCK signaling and thereby influence CCKR-mediated processes. We have set up a quantitative heterologous assay with CHO cells over-expressing the rat CCK1 receptor to screen for such candidate molecules. Receptor activation, induced by agonist binding, is followed by an intracellular calcium increase, which was monitored using a fluorescent sensor dye. For quantification of the calcium increase, a population average technique using a fluorescence plate reader was optimized and subsequently compared with a single-cell approach using confocal microscopy. With both strategies, dose-response curves were generated for the natural agonist CCK-8S, the partial agonist JMV-180 as well as the antagonist lorglumide. Significant differences were found between the ligands and a strong correspondence was observed between both methods in terms of maximum response and median effect concentrations. Both highly sensitive methods proved complementary: whereas the plate reader assay allowed faster, high throughput screening, the confocal microscopy identified single-cell variations and revealed factors that reduce specificity and sensitivity.
Collapse
|
2
|
Wu CL, Doong ML, Wang PS. Involvement of cholecystokinin receptor in the inhibition of gastrointestinal motility by oxytocin in ovariectomized rats. Eur J Pharmacol 2007; 580:407-15. [PMID: 18078924 DOI: 10.1016/j.ejphar.2007.11.024] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2007] [Revised: 10/29/2007] [Accepted: 11/10/2007] [Indexed: 01/04/2023]
Abstract
The effects of oxytocin on gastric emptying, gastrointestinal transit, and plasma levels of cholecystokinin (CCK) were studied in ovariectomized rats. Gastrointestinal motility was assessed in rats 15 min after intragastric instillation of a test meal containing charcoal and Na2 51CrO4. Gastric emptying was determined by measuring the amount of radiolabeled chromium contained in the small intestine as a percentage of the initial amount received. Gastrointestinal transit was evaluated by calculating the geometric center of distribution of the radiolabeled marker. Blood samples were collected for CCK radioimmunoassay. After administration of oxytocin (0.2-0.8 mg/kg), gastric emptying and gastrointestinal transit were inhibited, whereas plasma concentration of CCK was increased in a dose-dependent manner. Atosiban, an oxytocin receptor antagonist, effectively attenuated the oxytocin-induced inhibition of gastric emptying and gastrointestinal transit. However, administration of atosiban alone had no effect on gastric emptying and gastrointestinal transit. The selective CCK1 receptor antagonists, devazepide and lorglumide, effectively attenuated the oxytocin-induced inhibition of gastric emptying and gastrointestinal transit. L-365, 260, a selective CCK2 receptor antagonist, did not alter the oxytocin-induced inhibition of gastric emptying and gastrointestinal transit. These results suggest that oxytocin inhibits gastric emptying and gastrointestinal transit in ovariectomized rats via a mechanism involving the stimulation of CCK release and CCK1 receptor activation.
Collapse
Affiliation(s)
- Chiu-Lung Wu
- Department of Basic Medical Science, Hung-Kuang University, Taiwan, ROC.
| | | | | |
Collapse
|
3
|
Wu CL, Hung CR, Chang FY, Lin LC, Pau KYF, Wang PS. Effects of evodiamine on gastrointestinal motility in male rats. Eur J Pharmacol 2002; 457:169-76. [PMID: 12464363 DOI: 10.1016/s0014-2999(02)02687-0] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The effects of evodiamine on gastric emptying, gastrointestinal transit, and plasma levels of cholecystokinin (CCK) were studied in male rats. Evodiamine, isolated from the dry unripened fruit of Evodia rutaecarpa Bentham (a Chinese medicine named Wu-chu-yu), has been recommended for abdominal pain, acid regurgitation, nausea, diarrhea, and dysmenorrhea. Gastrointestinal motility was assessed in rats 15 min after intragastric instillation of a test meal containing charcoal and Na(2)51CrO(4). Gastric emptying was determined by measuring the amount of radiolabeled chromium contained in the small intestine as a percentage of the initial amount received. Gastrointestinal transit was evaluated by calculating the geometric center of distribution of the radiolabeled marker. Blood samples were collected for CCK radioimmunoassay (RIA). After administration of evodiamine (0.67-6.00 mg/kg), both gastric emptying and gastrointestinal transit were inhibited, whereas the plasma concentration of CCK was increased in a dose-dependent manner. The selective CCK(1) receptor antagonists, devazepide and lorglumide, effectively attenuated the evodiamine-induced inhibition of gastric emptying and gastrointestinal transit. L-365,260 (3R-(+)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-yl)-N'-(3-methylphenyl)-urea), a selective CCK(2) receptor antagonist, did not alter the evodiamine-induced inhibition of gastric emptying and gastrointestinal transit. These results suggest that evodiamine inhibits both gastric emptying and gastrointestinal transit in male rats via a mechanism involving CCK release and CCK(1) receptor activation.
Collapse
Affiliation(s)
- Chiu-Lung Wu
- Department of Physiology, School of Medicine, National Yang-Ming University, Shih-Pai, Taipei 11221, Taiwan, ROC
| | | | | | | | | | | |
Collapse
|
4
|
de Tullio P, Delarge J, Pirotte B. Therapeutic and chemical developments of cholecystokinin receptor ligands. Expert Opin Investig Drugs 2000; 9:129-46. [PMID: 11060666 DOI: 10.1517/13543784.9.1.129] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Cholecystokinin (CCK) is an important 'brain-gut' hormone located both in the gastrointestinal (GI) system and in the CNS. At least two different G-coupled high affinity receptors have been identified: the CCK-A and the CCK-B receptors. Although the complex biological role of CCK is, as yet, not fully understood, its connection with many different physiological processes both at the GI level and at the CNS level is now well established. There is much potential for therapeutic use of CCK receptor ligands, however, clear investigations have yet to be completed. Several chemical families have been investigated over the last 20 years to find potent, subtype selective and stable CCK receptor agonists and antagonists. The main goal was to discover new therapeutic drugs acting on GI and/or on CNS diseases and also, to obtain powerful pharmacological tools that could permit a better understanding of the biological role of CCK. Despite promising results from investigations into medicinal chemistry of CCK receptor ligands, the therapeutical applications of these ligands still remains to be defined. This article reviews the main biological role of CCK, the therapeutic potential of CCK-A and CCK-B receptor agonists and antagonists and the common compounds from the different families of ligands.
Collapse
Affiliation(s)
- P de Tullio
- Department of Medicinal Chemistry, Université de Liège, CHU, Avenue de l'Hôpital 1, B-4000 Sart-Tilman (Liège), Belgium.
| | | | | |
Collapse
|
5
|
Doong ML, Lu CC, Kau MM, Tsai SC, Chiao YC, Chen JJ, Yeh JY, Lin H, Huang SW, Chen TS, Chang FY, Wang PS. Inhibition of gastric emptying and intestinal transit by amphetamine through a mechanism involving an increased secretion of CCK in male rats. Br J Pharmacol 1998; 124:1123-30. [PMID: 9720782 PMCID: PMC1565493 DOI: 10.1038/sj.bjp.0701937] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
1. The effect of amphetamine on gastrointestinal (GI) transit and the plasma levels of cholecystokinin (CCK) were studied in male rats. 2. Gastric emptying was inhibited both acutely and chronically by the administration of amphetamine. GI transit was decreased by the acute administration of amphetamine but not affected by the chronic administration of amphetamine. 3. Plasma CCK levels were increased dose-dependently by amphetamine. 4. Proglumide, a CCK receptor antagonist, prevented amphetamine-induced inhibition of gastric emptying and the decrease in GI transit in male rats. 5. The selective CCK(A) receptor antagonist, lorglumide, dose-dependently attenuated the amphetamine-induced inhibition of gastric emptying in male rats. In contrast, the selective CCK(B) receptor antagonist, PD 135,158, did not reverse the effect of amphetamine on gastric emptying. 6. Both lorglumide and PD 135,158 reversed the inhibitory effect of amphetamine on GI transit in male rats. 7. These results suggest that amphetamine-induced inhibition of gastric emptying and intestinal transit is due in part to a mechanism associated with the hypersecretion of endogenous CCK.
Collapse
Affiliation(s)
- M L Doong
- Department and Graduate Institute of Physiology, National Yang-Ming University, Taipei, Taiwan, Republic of China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Meereis-Schwanke K, Klonowski-Stumpe H, Herberg L, Niederau C. Long-term effects of CCK-agonist and -antagonist on food intake and body weight in Zucker lean and obese rats. Peptides 1998; 19:291-9. [PMID: 9493861 DOI: 10.1016/s0196-9781(97)00261-1] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The present study evaluates long-term effects of the CCK-agonist caerulein and the CCK-A antagonist loxiglumide in obese and lean Zucker rats. Caerulein and loxiglumide altered food intake neither in obese nor in lean rats. By as yet unknown mechanisms, however, weight increase was accelerated by loxiglumide and reduced by caerulein in obese and lean rats. Caerulein increased pancreatic weight only in lean but not in obese rats. Thus, obese rats show a resistance of pancreatic CCK-A receptors. The failure of CCK-agonist and -antagonist to alter food intake suggests that this CCK-resistance is not responsible for obesity in the genetically altered rats.
Collapse
|
7
|
Niederau C, Meereis-Schwanke K, Klonowski-Stumpe H, Herberg L. CCK-resistance in Zucker obese versus lean rats. REGULATORY PEPTIDES 1997; 70:97-104. [PMID: 9272621 DOI: 10.1016/s0167-0115(97)00014-1] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Obese Zucker rats are less sensitive to the satiety effect of CCK than lean litter mates. The present studies further characterised this CCK resistance. Subcutaneous injection of the CCK agonist caerulein dose-dependently decreased food intake in Zucker obese and lean rats whereas the CCK-B agonist gastrin-17 did not. Caerulein at 4 microg/kg, which resulted in CCK plasma bioactivity slightly above postprandial levels, decreased food intake in lean rats but not in obese rats. The decrease in food intake was also more marked at higher caerulein doses (20-100 microg/kg) in lean versus obese rats. In lean animals the satiety effects of the "near physiological" 4 microg/kg caerulein dose was abolished after blockade of vagal afferents with capsaicin, whereas the effects of higher caerulein doses were not. CCK-stimulated amylase secretion from pancreatic acini and binding capacity of 125I-labelled CCK-8 were decreased in obese versus lean rats. The CCK-A antagonist loxiglumide at 20 mg/kg, a dose which abolished the action of all caerulein doses on food intake, failed to alter the food intake either in obese or in lean rats when given without an agonist. The results suggest that the satiety effects of "near physiological" doses of caerulein in lean rats are mediated by vagal afferents whereas pharmacological doses act via non-vagal mechanisms. The differences in CCK's satiety effect between lean and obese rats may be due to differences in CCK-receptor binding and action at peripheral vagal sites. However, the failure of the CCK-A antagonist to increase food intake questions whether any of the effects of exogenous CCK are of physiological relevance.
Collapse
Affiliation(s)
- C Niederau
- Department of Medicine, Heinrich-Heine-University, Düsseldorf, Germany.
| | | | | | | |
Collapse
|
8
|
Corp ES, Curcio M, Gibbs J, Smith GP. The effect of centrally administered CCK-receptor antagonists on food intake in rats. Physiol Behav 1997; 61:823-7. [PMID: 9177553 DOI: 10.1016/s0031-9384(96)00561-6] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Cholecystokinin (CCK) receptors are classified as two subtypes, designated CCK(A) and CCK(B), and both subtypes are found in brain and peripheral tissues of rats. CCK-8 has been shown to act peripherally to reduce meal size, and this satiating action can be blocked by CCK(A)-receptor antagonists. Recent evidence suggests that, in addition to the peripheral action of CCK, central CCK mechanisms may also be involved in satiety. Central administration of proglumide, a mixed CCK-receptor antagonist (CCK(A) > CCK(B)) has been shown to increase food intake and block the satiating effect of peripherally administered CCK-8 (15). In an attempt to replicate and extend these results, rats were given injections of proglumide or selective CCK-receptor antagonists into the lateral ventricle prior to a peripheral injection of CCK-8 or saline. Only proglumide stimulated an increase in 30-min test meal intake and attenuated the satiating effect of CCK-8. Two selective CCK(A)-receptor antagonists, lorglumide and devazepide, did not increase intake significantly when given alone, and they did not attenuate the effect of peripherally administered CCK-8. The selective CCK(B)-receptor antagonist, L365,260, reduced intake at all doses tested except the lowest. The lowest dose did not increase intake when given alone and did not attenuate the inhibitory effect of CCK on test-meal intake. Finally, a combination of devazepide and L365,260 did not increase intake or block the effect of peripherally administered CCK-8. These results suggest that CCK released by neurons in the brain and acting on central CCK(A)- and CCK(B)-receptors is not necessary for the control of meal size or for the satiating effect of peripherally administered CCK-8 in rats under our experimental conditions.
Collapse
Affiliation(s)
- E S Corp
- Department of Psychiatry, Cornell University Medical College, The New York Hospital-Cornell Medical Center, White Plains 10605, USA.
| | | | | | | |
Collapse
|
9
|
Abstract
Cholecystokinin (CCK) has emerged as an important mammalian neuropeptide, localized in peripheral organs and in the central nervous system. This review presents an overview of the molecular aspects of CCK peptides and CCK receptors, the anatomical distribution of CCK, the neurophysiological actions of CCK, release of CCK and effects of CCK on release of other neurotransmitters, and the actions of CCK on digestion, feeding, cardiovascular function, respiratory function, neurotoxicity and seizures, cancer cell proliferation, analgesia, sleep, sexual and reproductive behaviors, memory, anxiety, and dopamine-mediated exploratory and rewarded behaviors. Human clinical studies of CCK in feeding disorders and panic disorders are described. New findings are presented on potent, nonpeptide CCK antagonists, selective for the two CCK receptor subtypes, which demonstrate that endogenous CCK has biologically important effects on physiology and behavior.
Collapse
Affiliation(s)
- J N Crawley
- Section on Behavioral Neuropharmacology, National Institute of Mental Health, Bethesda, MD 20892
| | | |
Collapse
|
10
|
Revel L, Ferrari F, Makovec F, Rovati LC, Impicciatore M. Characterization of antigastrin activity in vivo of CR 2194, a new R-4-benzamido-5-oxo-pentanoic acid derivative. Eur J Pharmacol 1992; 216:217-24. [PMID: 1397008 DOI: 10.1016/0014-2999(92)90363-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The antigastrinic activity, in vivo, of CR 2194 (R-4-(3-chlorobenzamido)-5-(8-azaspiro[4.5]decan-8-yl) -5-oxo pentanoic acid) was assessed in various animal species. CR 2194 antagonized pentagastrin-stimulated gastric acid secretion in the rat (ID50 = 11 mg/kg i.v.), dog (ID50 = 5.9 mk/kg i.v. or 28.8 mg/kg os) and cat (ID50 = 15.5 mg/kg i.v.). CR 2194, in the cat, inhibited both competitively and non-competitively the gastric acid secretion stimulated with increased doses of pentagastrin, with a pA2 of 4.89. In the rat and in the dog the antagonism seemed to be non-competitive and the respective pD'2 calculated were 4.54 and 4.42. The interaction of CR 2194 with the gastrin receptors appeared reversible, as demonstrated by the return to normal values of the acid output after the conclusion of the i.v. infusion, during pentagastrin continuous stimulation in the dog. The antigastrin activity was specific: CR 2194 was unable to antagonize the gastric acid secretion stimulated by carbachol or histamine in the rat up to the dose of 100 mg/kg. CR 2194 was effective to antagonize the gastric acid secretion stimulated by gastrin release after meal ingestion in the Heidenhain pouch dog model. The ID50 calculated was 2.89 mg/kg after oral administration. All these characteristics make CR 2194 an important compound in the investigation of the biological effects of gastrin and a potential agent for diagnostic or therapeutic use.
Collapse
Affiliation(s)
- L Revel
- Rotta Research Laboratorium, Monza, Milano, Italy
| | | | | | | | | |
Collapse
|
11
|
Asin KE, Gore PA, Bednarz L, Holladay M, Nadzan AM. Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats. Brain Res 1992; 571:169-74. [PMID: 1611492 DOI: 10.1016/0006-8993(92)90527-g] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
In this paper report the effects of peripheral (intraperitoneal, i.p.) and central (intracerebroventricular, i.c.v.) injection of selective cholecystokinin (CCK) receptor agonists on food intake in the rat. Stimulation of peripheral and central CCK-A receptors by the selective CCK-A receptor agonist A-71623 suppressed intakes of a liquid diet in both deprived and sated rats. In contrast, i.c.v., but not i.p., injections of the selective CCK-B receptor agonist A-63387, reduced food intakes, although on a molar basis the effect was much less than that seen with A-71623. Although these results stress the relative importance of the CCK-A receptor in the effects of exogenous CCK-8 administration on feeding, stimulation of the CCK-B receptor may still be involved in the control of feeding following the endogenous release of CCK.
Collapse
Affiliation(s)
- K E Asin
- Neuroscience Research Division, Abbott Laboratories Abbott Park, IL 60064
| | | | | | | | | |
Collapse
|
12
|
Murphy RB, Smith GP, Schneider LH, Gibbs J. Peripheral factors in the mediation of cholecystokinin-induced satiety as assessed by comparative potencies of cholecystokinin antagonists. Peptides 1992; 13:77-81. [PMID: 1620660 DOI: 10.1016/0196-9781(92)90143-q] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Cholecystokinin COOH-terminal octapeptide (CCK-8) produces a satiating effect in the rat and other animals upon peripheral administration. Although it has been demonstrated that the receptors which mediate this action are located in the periphery and are of the CCK-A subtype, their anatomical location has not been firmly established. A dense population of CCK receptors in the pyloric sphincter has been suggested as a candidate. We here quantify the potency of several CCK antagonists to inhibit the contractile effect of CCK-8 on the rat pyloric sphincter in vitro. The potent and selective antagonist MK-329 has a Schild pK of 8.85; the less potent but selective antagonist lorglumide (CR-1409) a pK of 6.37; the related antagonist phenoxyacetylproglumide (phi oAc proglumide) a pK of 5.1; and the weak parent compound proglumide a pK of about 3.3. These data can be compared with the potencies of these compounds to inhibit the actions of CCK-8 to produce satiety in the rat; this comparison supports the contention that CCK receptors of the rat pyloric sphincter could in part mediate the satiety effect produced by exogenous CCK-8.
Collapse
Affiliation(s)
- R B Murphy
- Department of Psychiatry, Cornell University Medical College, New York Hospital-Cornell Medical Center, White Plains 10605
| | | | | | | |
Collapse
|
13
|
Södersten P, Forsberg G, Bednar I, Lindén A, Qureshi GA. Cholecystokinin in the control of ingestive behavior. PROGRESS IN BRAIN RESEARCH 1992; 92:335-43. [PMID: 1302882 DOI: 10.1016/s0079-6123(08)61187-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- P Södersten
- Department of Psychiatry and Clinical Research Center, Karolinska Institute, Huddinge, Sweden
| | | | | | | | | |
Collapse
|
14
|
Koshikawa N, Kikuchi de Beltrán K, Saigusa T, Kobayashi M, Stephenson JD. Cholecystokinin octapeptide and caerulein injection into the dorsomedial nucleus accumbens potentiate apomorphine-induced jaw movements in rats. Eur J Pharmacol 1991; 209:75-80. [PMID: 1814762 DOI: 10.1016/0014-2999(91)90013-g] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The effects of bilateral intra-accumbal and intrastriatal injections of CCK-8 sulphate and its analogue, caerulein, on apomorphine-induced jaw movements were studied in ketamine-anaesthetized rats after C1 spinal transection. Jaw movements were detected by a photo-transducer attached to the mandible. CCK-8 (5, 10 and 20 ng) and its analogue, caerulein (1 and 5 ng), injected into the dorsomedial nucleus accumbens increased the frequency of apomorphine (0.2 mg/kg i.v.)-induced jaw movements. The potentiation was prevented by administration of a CCK-A receptor antagonist, lorglumide (5 ng), together with CCK-8 (20 ng) or caerulein (5 ng). Injection of lorglumide alone into the dorsomedial nucleus accumbens did not alter apomorphine (0.5 mg/kg i.v.)-induced jaw movements. Injections of CCK-8 (20 ng) and caerulein (5 ng) into adjacent sites (the ventrolateral nucleus accumbens, dorsal striatum and ventral striatum) did not affect the responses elicited by apomorphine (0.2 mg/kg i.v.). These results demonstrate that CCK-8 modulates responses elicited by a dopamine receptor agonist, apomorphine, in a region of the brain where CCK-8 is known to co-exist with dopamine.
Collapse
Affiliation(s)
- N Koshikawa
- Department of Pharmacology, Nihon University School of Dentistry, Tokyo, Japan
| | | | | | | | | |
Collapse
|
15
|
Spencer GS, Berry C, Johnston S. Neuroendocrine regulation of growth hormone secretion in sheep. IV. Central and peripheral cholecystokinin. Domest Anim Endocrinol 1991; 8:555-63. [PMID: 1786702 DOI: 10.1016/0739-7240(91)90025-f] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The result of alterations in the levels of CCK, in the blood and in the cerebrospinal fluid, on the functioning of the growth hormone axis has been examined in sheep. Male Coopworth sheep of about 40 kg liveweight were given various doses of CCK either intracerebroventricularly (icv) or intravenously (iv). Other similar sheep were given various doses of a CCK antagonist (loxiglumide) by the same routes. Bolus iv administration of either 35 micrograms or 200 micrograms of CCK had no effect on plasma GH levels. When given icv, however, CCK resulted in a marked (P less than 0.01) prolonged depression in plasma GH levels. The decrease in GH secretion could be partially attenuated by concurrent administration of loxiglumide, but was completely unaffected by concurrent administration of antisomatostatin serum icv. Loxiglumide alone had no effect on plasma GH levels when given at up to 200 micrograms icv, but intravenous administration of 8 mg of the CCK antagonist resulted in an increase in plasma GH concentrations (P less than 0.05). Plasma levels of somatostatin, glucose and cortisol were unaffected by both icv and iv administration of CCK. These results show that CCK can have a strong GH-inhibiting effect in the brain. Furthermore, this effect seems to be independent of hypothalamic somatostatin, suggesting another GH-inhibiting system exists.
Collapse
Affiliation(s)
- G S Spencer
- Ruakura Agricultural Centre, Hamilton, New Zealand
| | | | | |
Collapse
|
16
|
Aired S, Creach Y, Palevody C, Esclassan J, Hollande E. Creatine phosphate as energy source in the cerulein-stimulated rat pancreas study by 31P nuclear magnetic resonance. INTERNATIONAL JOURNAL OF PANCREATOLOGY : OFFICIAL JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PANCREATOLOGY 1991; 10:81-95. [PMID: 1757733 DOI: 10.1007/bf02924256] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Stimulation of the rat exocrine pancreas by cerulein induces a variety of cellular processes, some of which require the expenditure of energy. In this study, changes in the amounts of various energy metabolites, including creatine phosphate (PCr), ATP, and ADP were determined by high-resolution 31P NMR spectroscopy. The spectrum of a perchloric acid extract of pancreas from the 48 h fasted rat was taken as a reference for comparison of 31P NMR spectra recorded after stimulation by cerulein. The NMR results obtained from rat pancreas stimulated in vivo by cerulein (3, 5, 10, 20, 40 min) were compared to those determined by HPLC. We show that during hormonal stimulation, the relative concentrations of PCr in the pancreas of the fasted rat rise significantly (p less than 0.02), reach a maximum at 10 min, fall between the 10th and 20th min, and then return to the relatively low levels observed in controls. On the other hand, the relative concentrations of ATP fall during the first 10 min after stimulation by cerulein, then rise significantly between the 10th and 20th min, whereas the levels of ADP rise during the first 10 min and fall between the 10th and 20th min. The energy required for exocytosis was assumed to be supplied by ATP synthesized in acinar cells. The 31P NMR results indicated that this ATP was derived from phosphorylation of ADP by PCr, and that large amounts of PCr are synthesized during the first minutes after cerulein stimulation. In addition, a significant rise in glycerophosphocholine was observed after cerulein stimulation, which was attributed to an enhanced catabolism of membranes and an increase in phospholipid turnover. Injection of cerulein antagonists, such as asperlicin or lorglumide, inhibited the effects of cerulein stimulation on energy metabolites. Furthermore, no changes were observed after injection of secretin, a hormone that stimulates secretion of bicarbonate. However, the analog of cerulein, pentagastrin, produced the same effects as cerulein, although to a lesser extent.
Collapse
Affiliation(s)
- S Aired
- Laboratoire de Biologie Cellulaire, Université Paul Sabatier, Toulouse, France
| | | | | | | | | |
Collapse
|
17
|
Affiliation(s)
- G N Woodruff
- Parke Davies Research Unit, Addenbrookes Hospital Site, Cambridge, UK
| | | | | | | | | | | |
Collapse
|
18
|
Rovati LC. Perspectives of CCK antagonists in pancreatic research and clinical use. Part I. INTERNATIONAL JOURNAL OF PANCREATOLOGY : OFFICIAL JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PANCREATOLOGY 1991; 8:215-26. [PMID: 2051061 DOI: 10.1007/bf02924540] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Cholecystokinin (CCK) is one of the most important regulators of pancreatic and digestive physiology. Its importance led to research and discovery of a number of CCK receptor antagonists. Some of them are experimentally and clinically used today in order to assess the relative contribution of CCK to different aspects of pancreatic physiology. Furthermore, clinical trials are running with the aim of determining their possible therapeutic indications in pancreatic diseases, such as acute and chronic pancreatitis or pancreatic carcinoma. The rationale and evidence for their use are discussed.
Collapse
Affiliation(s)
- L C Rovati
- Department of Clinical Pharmacology, Rotta Research Laboratorium, Milan, Italy
| |
Collapse
|
19
|
Lindén A, Uvnäs-Moberg K, Forsbergt G, Bednar I, Södersten P. Involvement of cholecystokinin in food intake: I. Concentrations of cholecystokinin-like immunoreactivity in the cerebrospinal fluid of male rats. J Neuroendocrinol 1990; 2:783-9. [PMID: 19215419 DOI: 10.1111/j.1365-2826.1990.tb00641.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Abstract To investigate the role of central neural cholecystokinin in food intake the concentration of cholecystokinin-like immunoreactivity was measured by radioimmunoassay in the cerebrospinal fluid of male rats. Characterization of the molecular forms of Cholecystokinin was made by high-performance liquid chromatography before radioimmunoassay. Four molecular forms of cholecystokinin corresponding to standards of the tetra-, penta- and sulphated octapeptide and a late eluting peak probably corresponding to cholecystokinin-58 were found. The concentration of cholecystokinin-like immunoreactivity in the cerebrospinal fluid decreased in response to 48 h of food deprivation and was restored after 1 h of food intake, the main increase occurring within 30 min after the onset of feeding. Cholecystokinin-like immunoreactivity increased in the cerebrospinal fluid 10 min after an intraperitoneal injection of 5 mug cholecystokinin octapeptide, a dose which also suppressed the amount of food consumed during 1 h in rats deprived of food for 48 h. Intraperitoneal injection of the peripheral, cholecystokinin A receptor antagonists lorglumide (450 mug) or L-364. 718 (20 mug) reversed the inhibitory effect of cholecystokinin octapeptide on food intake and prevented the increase of cholecystokinin-like immunoreactivity in the cerebrospinal fluid. It is suggested that central neural cholecystokinin is involved in the control of food intake and that this is reflected in the alterations in cholecystokinin-like immunoreactivity in the cerebrospinal fluid which occur in response to food deprivation and food intake. However, a variety of ways of intracerebral administration of Cholecystokinin octapeptide failed to affect food intake in food-deprived rats. The possibility is raised that Cholecystokinin octapeptide acts in concert with another transmitter in the brain to affect food intake.
Collapse
Affiliation(s)
- A Lindén
- Department of Pharmacology, Karolinska Institute, S-104 01 Stockholm, Sweden
| | | | | | | | | |
Collapse
|
20
|
Lindén A, Södersten P. Relationship between the concentration of cholecystokinin-like immunoreactivity in plasma and food intake in male rats. Physiol Behav 1990; 48:859-63. [PMID: 2087518 DOI: 10.1016/0031-9384(90)90240-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
In food-deprived male rats IP injection of cholecystokinin octapeptide (CCK-8, 5 micrograms), ingestion of food or ejaculation caused a comparable increase in plasma concentrations of CCK-8 and inhibited food intake. IV injection of 0.1 microgram CCK-8 interrupted ongoing feeding and greatly increased plasma CCK-8 levels. Osmotic minipumps delivering 0.5 micrograms CCK-8/h implanted IP reduced meal size and caused a modest increase in plasma CCK-8 levels. Injection of 5 micrograms CCK-8 IP produced an abrupt but transient increase in plasma CCK-8 concentrations whereas plasma concentrations of CCK-8 increased gradually with feeding. Injection of 5 micrograms CCK-8 IP, but not feeding, caused a marked increase in plasma oxytocin levels. The suppression of feeding, but not the increase in oxytocin, induced by IP CCK-8 was reversed by ICV injection of the CCK antagonist proglumide in a dose (100 micrograms) which failed to affect food intake if injected IP. Deprivation of food decreased and feeding increased the concentration of CCK-like immunoreactivity in the CSF. It is suggested that CCK-8 inhibits feeding in physiological doses by a specific mechanism in which peripheral as well as central neural CCK is involved.
Collapse
Affiliation(s)
- A Lindén
- Department of Psychiatry, Karolinska Institute, Huddinge, Sweden
| | | |
Collapse
|
21
|
Takaki A, Nagai K, Takaki S, Yanaihara N, Nakagawa H. Satiety function of neurons containing a CCK-like substance in the dorsal parabrachial nucleus. Physiol Behav 1990; 48:865-71. [PMID: 2087519 DOI: 10.1016/0031-9384(90)90241-u] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Glutaryl-CCK-8 (Glt-CCK-8, 16-160 pmol) suppressed food intake dose dependently when injected into the ventromedial hypothalamus (VMH) bilaterally, but not when injected unilaterally. In contrast, CCK-8 (160 and 320 pmol) did not suppress food intake when injected into the VMH bilaterally. When injected intraperitoneally, Glt-CCK-8 significantly decreased food intake at a dose of 320 pmol, though not at a dose of 160 pmol, whereas CCK-8 significantly reduced food intake even at a dose of 160 pmol. Pretreatment with proglumide, an antagonist of CCK-8, counteracted the effect on food intake of CCK-8 injected intraperitoneally, but did not influence that of Glt-CCK-8 injected either into the VMH or intraperitoneally. However, CCK-8 (800 pmol) prevented the satiety action of Glt-CCK-8 when injected into the VMH before the latter. Since a large dose of CCK-8 injected into the VMH was reported to suppress food intake, these findings suggest that, among the receptors for the satiety action of CCK, intracranial receptor has lower affinity for CCK-8 than for Glt-CCK-8 and peripheral receptor has higher affinity for CCK-8 than for Glt-CCK-8. Furthermore, bilateral lesions of the lateral part of the dorsal parabrachial nucleus (LPBD), from which the neurons containing a CCK-8-like substance extend fibers to the VMH, enhanced the satiety action of Glt-CCK-8 injected into the VMH. These results support the idea that these neurons which project to the VMH are involved in the satiety action.
Collapse
Affiliation(s)
- A Takaki
- Division of Protein Metabolism, Osaka University, Japan
| | | | | | | | | |
Collapse
|
22
|
|
23
|
Mulholland MW, Debas HT. Cholecystokinin receptor antagonism of stimulated pancreatic and gastric secretion. J Surg Res 1989; 47:460-4. [PMID: 2478762 DOI: 10.1016/0022-4804(89)90102-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The effects of cholecystokinin receptor antagonist, dipentyl-3,4-dichloroproglumide (DDP), on stimulated pancreatic and gastric secretion were studied in the rat. DDP dose-dependently inhibited cholecystokinin-stimulated amylase release from dispersed acinar cells. In vivo, DDP inhibited cholecystokinin octapeptide-stimulated amylase and protein secretion. DDP also inhibited pentagastrin-stimulated gastric acid secretion in vivo. Meal-stimulated acid output was decreased by 34% (DDP 400 micrograms/kg/hr) but responsiveness to histamine or parachlorophenyl-gamma-aminobutyric acid was unchanged.
Collapse
Affiliation(s)
- M W Mulholland
- Department of Surgery, University of Michigan, Ann Arbor 49109
| | | |
Collapse
|
24
|
Leighton GE, Griesbacher T, Hill RG, Hughes J. Antagonism of central and peripheral anorectic effects of caerulein by L-364,718. Eur J Pharmacol 1989; 161:255-8. [PMID: 2721558 DOI: 10.1016/0014-2999(89)90855-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
The reduction in food intake induced by i.p. injections of the cholecystokinin (CCK) analogue caerulein was antagonised by a low dose (0.25 mumol/kg s.c.) of the selective CCK antagonist L-364,718. To block the anorectic effect of centrally administered caerulein a dose of 25 mumol/kg of L-364,718 was required, demonstrating that central CCK receptors can be blocked effectively in the rat by choosing appropriate doses of L-364,718.
Collapse
Affiliation(s)
- G E Leighton
- Parke-Davis Research Unit, Addenbrookes Hospital Site, Cambridge, U.K
| | | | | | | |
Collapse
|
25
|
Griesbacher T, Leighton GE, Hill RG, Hughes J. Reduction of food intake by central administration of cholecystokinin octapeptide in the rat is dependent upon inhibition of brain peptidases. Br J Pharmacol 1989; 96:236-42. [PMID: 2647203 PMCID: PMC1854319 DOI: 10.1111/j.1476-5381.1989.tb11805.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
1. The effects of intracerebroventricular (i.c.v.) injections of cholecystokinin-octapeptide (CCK-8) and caerulein, an amphibian decapeptide structurally related to CCK-8, are inconsistent in the rat. We have therefore investigated the possibility that enzymatic degradation could be responsible for the lack of activity of CCK-8 seen in some studies on food intake. 2. Injections of CCK-8 at doses of 2.5 nmol and 25 nmol into the lateral cerebral ventricle of rats did not reduce the intake of a highly palatable diet whereas injections of the same doses of caerulein reduced food intake potently and dose-dependently. 3. Co-administration of CCK-8 with a combination of the peptidase inhibitors bestatin (70 nmol), captopril (100 nmol) and thiorphan (120 nmol) resulted in an inhibition of feeding similar to that seen after the injection of caerulein alone. The peptidase inhibitors alone did not affect food intake. 4. When caerulein was injected i.c.v. in combination with bestatin, captopril and thiorphan the effect of caerulein was potentiated, suggesting that enzymatic breakdown of caerulein does occur. 5. It is concluded that the effect of centrally administered CCK-8 on food intake is dependent on the activity of cleaving enzymes in the brain. It is emphasized that the action of brain peptidases is a major factor which has to be considered when investigating the role of peptides in the central nervous system.
Collapse
Affiliation(s)
- T Griesbacher
- Parke-Davis Research Unit, Addenbrookes Hospital Site, Cambridge
| | | | | | | |
Collapse
|
26
|
Itoh S, Takashima A. Effect of cholecystokinin octapeptide antagonists on the extinction of an active avoidance task in the rat. Drug Dev Res 1989. [DOI: 10.1002/ddr.430170109] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
27
|
Schneider LH, Murphy RB, Smith GP. Two proglumide analogues are equipotent antagonists of the inhibition of food intake by CCK-8. Peptides 1988; 9 Suppl 1:207-14. [PMID: 2856646 DOI: 10.1016/0196-9781(88)90246-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The reduction in food intake produced by exogenous CCK-8 (8 micrograms.kg-1, IP) in 18 hr food-deprived rats was significantly reversed by either of two proglumide analogues at doses of 0.44 and 4.4 microM.kg-1. The two glutamic acid derivatives tested were CR-1409 [N-(3,4-dichlorobenzoyl)-L-glutamic acid-1-di-n-pentylamide], effective at doses of 0.2 and 2.0 mg.kg-1, IP, and PGDPA [N-(phenoxyacetyl)-L-glutamic acid-1-di-n-propylamide], effective at the equimolar doses of 0.16 and 1.6 mg.kg-1, IP, as well as at 16 mg.kg-1 (44 microM.kg-1). By comparison, proglumide reversed the inhibition of food intake by CCK-8 at 160 mg.kg-1 (470 microM.kg-1), but not at 16 mg.kg-1 (47 microM.kg-1). At the 0.44 microM.kg-1 dose which antagonized CCK-8-induced satiety, neither PGDPA nor CR-1409 reduced the inhibition of food intake induced by bombesin, supporting the behavioral specificity of these CCK antagonists. Previous in vitro studies have shown that CR-1409 was approximately 4000-fold more potent than proglumide and PGDPA was 100-fold more potent than proglumide as antagonists of CCK-8-induced amylase secretion and binding in pancreatic acinar cells. Here, we found no potency difference between PGDPA and CR-1409; each was more than 1000-fold more potent than proglumide as an antagonist of the inhibition of food intake produced by CCK-8. This nonparallelism between the potencies of these antagonists at CCK receptors located upon pancreatic acinar cells and at CCK receptors involved in CCK-8-induced satiety suggests that the two receptor populations differ pharmacologically.
Collapse
Affiliation(s)
- L H Schneider
- Department of Psychiatry, Cornell University Medical College, White Plains, NY
| | | | | |
Collapse
|